Compare BioNano Genomics Inc (BNGO) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs IAC/Interactivecorp — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.66M), while IAC/Interactivecorp trades at $40.14 (market cap $2.97B). The key difference: IAC/Interactivecorp is far larger — about 217.4× BioNano Genomics Inc's market cap, and IAC/Interactivecorp is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | PPLI | |
|---|---|---|
Market Cap | $13.66M | $2.97B |
Sector | Health | Media |
52-Week High | $4.92 | $47.62 |
52-Week Low | $1.06 | $31.52 |
Enterprise Value | $16.26M | $3.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
PPLI trades at $40.66, down 2.21% today, with a bearish technical signal but strong analyst support. Recent Q2 2026 earnings beat expectations with EPS of $6.77, driven by digital growth and MGM investment gains. The company is simplifying its structure and monetizing non-core assets. Valuation ratios appear attractive with a P/E of 6.76 and P/B of 0.59, though revenue has declined from $5.2B in 2022 to $2.4B in 2025.
Outlook is mixed: low valuation and asset monetization offer upside, but declining revenue and volatile earnings pose risks. Analyst consensus is bullish with a $60.50 price target, implying 49% potential upside. Key risks include execution of restructuring and dependence on MGM performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
